Telehealth Intervention for Symptom Management and Adherence to Adjuvant Endocrine Therapy

The goal of this study is to demonstrate the efficacy of an evidence-based, small-group, telehealth intervention ('STRIDE') for improving patients' ability to cope with side effects from adjuvant endocrine therapy (AET) and adhere to AET medication regimens for patients with hormone-sensitive breast cancer.

Inclusion Criteria: * Female ≥ 21 years old * Diagnosis of early-stage (0-IIIb), hormone receptor positive (ER+/PR+) breast cancer * Completed primary treatment (surgery, chemotherapy, and/or radiation) * Within 3 to 12 months of starting oral adjuvant endocrine therapy (AET) * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Ability to read and respond in English or Spanish * Distress about AET ≥ 4 on a 0-10 scale Exclusion Criteria: * Cognitive impairment, uncontrolled psychosis, or serious mental illness prohibiting participation in the study as per the judgment of the treating oncologist * Enrolled in a clinical trial for AET